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Introduction {#jdi12895-sec-0005}
============

Type 2 diabetes is a metabolic disorder that is characterized by abnormal glucose homeostasis due to some defect in the secretion and/or action of insulin. There has been a dramatic increase in type 2 diabetes patients in East Asian countries, which now represent one‐quarter of the global diabetes population[1](#jdi12895-bib-0001){ref-type="ref"}. Although the precise mechanisms that underlie the development and progression of type 2 diabetes have not been fully elucidated, it is thought that a combination of multiple genetic and environmental factors contribute to the pathogenesis of the disease[2](#jdi12895-bib-0002){ref-type="ref"}. There has therefore been increased interest in reappraising animal models of type 2 diabetes in which genetic and environmental factors that could influence the development of the disease and related complications can be precisely controlled *in vivo* to help elucidate the etiology of diabetes and develop new medications. Animal models have made an enormous contribution to the study of diabetes mellitus, providing new information on its management and treatment in humans. Animal models for type 2 diabetes have been widely used for elucidating the genes responsible for the development of type 2 diabetes, the physiological course of the disease and related complications[3](#jdi12895-bib-0003){ref-type="ref"}, [4](#jdi12895-bib-0004){ref-type="ref"}.

Type 2 diabetes in East Asian people is characterized by a lower level of obesity compared with type 2 diabetes in Caucasian, as well as a younger age of onset[5](#jdi12895-bib-0005){ref-type="ref"}, [6](#jdi12895-bib-0006){ref-type="ref"} and β‐cell dysfunction[6](#jdi12895-bib-0006){ref-type="ref"}, [7](#jdi12895-bib-0007){ref-type="ref"}, [8](#jdi12895-bib-0008){ref-type="ref"}. Relatively few people with diabetes in Japan are obese, and the impairment of insulin secretion often develops before the onset of diabetes[9](#jdi12895-bib-0009){ref-type="ref"}. Thus, non‐obese animal models are required to elucidate the complete pathogenesis of diabetes. To this end, we have established a novel, non‐obese murine strain with spontaneous diabetes -- the insulin hyposecretion (*ihs*) mouse. The *ihs* mouse allows not only the analysis of the progression of diabetes, but also the identification of unknown genes involved in insulin secretion. The present study describes the development and characterization of the *ihs* mouse.

Methods {#jdi12895-sec-0006}
=======

Ethical statement {#jdi12895-sec-0007}
-----------------

All animal experiments were approved by the President of Kitasato University and National Center for Global Health and Medicine, following consideration by the Institutional Animal Care and Use Committee of Kitasato University (approval ID: no. 17‐099) and National Center for Global Health and Medicine (approval ID: no. 17056), and were carried out in accordance with institutional procedures, national guidelines and the relevant national laws on the protection of animals.

Breeding of congenic mice {#jdi12895-sec-0008}
-------------------------

The ICR‐derived glomerulonephritis (ICGN) mouse provides a model of glomerular dysfunction that shows gross morphological changes in the podocyte foot processes that accompany proteinuria (Appendix [S1](#jdi12895-sup-0008){ref-type="supplementary-material"}). Previously, we showed that proteinuria in ICGN mice was caused by a deletion mutation in the tensin2 (*Tns2*) gene (designated *Tns2* ^*nph*^)[10](#jdi12895-bib-0010){ref-type="ref"}, [11](#jdi12895-bib-0011){ref-type="ref"}. As the original ICGN mouse is a spontaneous mutant derived from closed colony ICR mice, there is no control strain. We therefore created a control strain by using classical breeding methods to introgress the wild‐type *Tns2* gene (*Tns2* ^*WT*^) from the C57BL/6J (B6) mouse into the inbred ICGN strain (ICGN.B6‐*Tns2* ^*WT*^)[12](#jdi12895-bib-0012){ref-type="ref"}. We moved the *Tns2* ^*WT*^ allele onto the ICGN genetic background by backcrossing for 10 generations, and subsequently homozygous ICGN.B6‐*Tns2* ^*WT*^ */Tns2* ^*WT*^ mice were produced by sib mating. During this strain breeding process, we discovered mutant mice with polydipsia, polyuria, hyperglycemia and hypoinsulinemia, which we named *ihs* mice (Figure [1](#jdi12895-fig-0001){ref-type="fig"}). As *ihs* mice are spontaneous mutants derived from ICGN mice, which are an animal model for congenital nephrosis, B6 mice were used in the present study as a reference.

![The pedigree of insulin hyposecretion (*ihs*) mice developed from ICGN and C57BL/6J mice.](JDI-10-227-g001){#jdi12895-fig-0001}

Phenotype measurements {#jdi12895-sec-0009}
----------------------

The mice were weighed weekly from 5 weeks‐of‐age. The nasal‐anal length was measured, and the body mass index was calculated at 12, 25 and 52 weeks by taking the weight (g) and dividing it by the square of the nasal‐anal length (cm). Body composition was measured by NMR (LF50 BCA‐Analyzer; Bruker, Billerica, Massachusetts, USA).

Blood and urine analysis {#jdi12895-sec-0010}
------------------------

Urine glucose levels were measured semiquantitatively using Uro‐paper III (Eiken, Tokyo, Japan). To obtain paired measurements with urine glucose levels, blood was collected by tail snip immediately after urine collection. The blood glucose levels were measured using Glutest Ace and Glutest Sensor (Sanwa Chemical Co., Tokyo, Japan). Diabetes was diagnosed when the glucose level was \>250 mg/dL under *ad libitum* feeding conditions.

Oral glucose and insulin tolerance tests {#jdi12895-sec-0011}
----------------------------------------

The mice were fasted for 16 h, and tail blood glucose was measured at 0, 30, 60, 90 and 120 min after the oral administration of glucose (2 g/kg bodyweight; Otsuka Pharmaceutical, Tokyo, Japan) by gavage. Plasma samples were collected from the retro‐orbital venous plexus at 0, 15 and 30 min for insulin measurement. Plasma insulin levels were determined by an ultrasensitive mouse insulin kit (Morinaga Institute of Biological Science Inc., Kanagawa, Japan). The area under the curve (AUC) of insulin secretion was calculated after subtraction of the baseline insulin level at the time the glucose was administered.

An insulin tolerance test was carried out after the mice had fasted for 3 h. Insulin (0.75 unit/kg bodyweight; Humulin, Lilly, Indianapolis, Indiana, USA) was injected into the intraperitoneal space, and blood glucose levels were measured with a glucose monitor at 0, 30, 60, 90 and 120 min after the injection.

Other analyses {#jdi12895-sec-0012}
--------------

Non‐fasting plasma insulin and active glucagon‐like peptide‐1 (GLP‐1) levels were measured by enzyme‐linked immunosorbent assay (Appendices [S2 and S3](#jdi12895-sup-0008){ref-type="supplementary-material"}).

Insulin secretion from *in situ* perfused pancreata (Appendix [S4](#jdi12895-sup-0008){ref-type="supplementary-material"}) and insulin secreted by islets isolated from *ihs* mice (Appendix [S5](#jdi12895-sup-0008){ref-type="supplementary-material"}) were measured.

Pancreata were subjected to histological analysis, including an analysis of islet morphology, as described previously[13](#jdi12895-bib-0013){ref-type="ref"}, [14](#jdi12895-bib-0014){ref-type="ref"}. The details are given in Appendix [S6](#jdi12895-sup-0008){ref-type="supplementary-material"}.

RT‐qPCR for genes associated with monogenic diabetes was carried out. Details are presented in Appendix [S7](#jdi12895-sup-0008){ref-type="supplementary-material"} and Table [S1](#jdi12895-sup-0007){ref-type="supplementary-material"}.

Statistical analysis {#jdi12895-sec-0013}
--------------------

The results are expressed as mean ± standard error of the mean. Significant differences in AUC or reverse AUC were analyzed using unpaired Student\'s *t*‐tests. The results for insulin secretion from the *in situ* perfused pancreas analysis were analyzed using repeated‐measures [anova]{.smallcaps} and Student\'s *t*‐test. Student\'s *t*‐test was used for comparisons of two independent groups, respectively. A *P*‐value \<0.05 was considered statistically significant.

Results {#jdi12895-sec-0014}
=======

Incidence of diabetes, and survival {#jdi12895-sec-0015}
-----------------------------------

The cumulative incidence of diabetes in *ihs* mice, determined by the casual blood glucose level, is shown in Figure [2](#jdi12895-fig-0002){ref-type="fig"}a. Diabetes was observed only in male mice. The earliest onset was observed at 9--12 weeks, and its incidence increased with age (33 and 89% at 12 and 42 weeks, respectively). Glucosuria appeared in male mice at 9--12 weeks, concomitant with the onset of diabetes, and was present in 88.9% of mice aged 42 weeks (Figure [2](#jdi12895-fig-0002){ref-type="fig"}b). Because the onset of diabetes differed between the sexes, we focused our studies on male mice. At 45 weeks‐of‐age, the survival rate of the male *ihs* mice was approximately 50%, decreasing to approximately 42% at 51 weeks, compared with 81% survival at 51 weeks in female *ihs* mice (Figure [2](#jdi12895-fig-0002){ref-type="fig"}c). This indicated that the onset of diabetes influenced the survival of male *ihs* mice.

![The incidence of diabetes and the rate of survival in *ihs* mice. (a,b) The cumulative incidence of diabetes in *ihs* male (*n* = 18) and female (*n* = 16) mice. Diabetes is defined as a blood glucose level of ≥250 mg/dL under *ad libitum* feeding conditions. (c) Cumulative survival rate of *ihs* mice. The cumulative survival rate was plotted against age in weeks (*n * =  31 and 16 mice for male and female mice, respectively).](JDI-10-227-g002){#jdi12895-fig-0002}

Clinical features of the *ihs* mice {#jdi12895-sec-0016}
-----------------------------------

Aged 11 weeks, the *ihs* mice (32.4 ± 0.4 g, *n* = 10) were significantly lighter than the ICR mice (33.8 ± 1.9 g, *P *\< 0.01, *n* = 9). However, at 12 weeks, the *ihs* mice were heavier than the B6 strain mice (Figure [3](#jdi12895-fig-0003){ref-type="fig"}a). The bodyweight of the B6 mice continued to increase until 52 weeks‐of‐age, whereas growth in the *ihs* mice reached a plateau (35 g) at 25 weeks (Figure [3](#jdi12895-fig-0003){ref-type="fig"}b), with their weight gradually decreasing to approximately 61% of that of B6 mice at 52 weeks. A significant decrease in body weight was observed after the onset of diabetes. The two strains of mice had similar body mass index values at 25 weeks (Figure [3](#jdi12895-fig-0003){ref-type="fig"}c), indicating that the *ihs* mice were non‐obese. The analysis of body composition using the NMR method showed that the relative fat percentage was significantly lower in *ihs* mice, being approximately 47 and 20% of that of B6 mice at 25 and 52 weeks‐of‐age, respectively, with a concomitant increase in lean mass (Figure [3](#jdi12895-fig-0003){ref-type="fig"}d). These findings showed that the bodyweight reduction in *ihs* mice was largely due to decreased fat mass, thought to be associated with the onset of diabetes.

![Bodyweight, body mass index (BMI), body composition, water consumption and food intake in *ihs* mice. (a) Change in bodyweight in male *ihs* (*n* = 8) and B6 (*n* = 10). (b,c) Bodyweight in male *ihs* (*n* = 4) and B6 mice (*n* = 5) was measured at the indicated ages. BMI was calculated as bodyweight (g) divided by the square of the anal‐nasal length (cm^2^) at the indicated ages. (d) Comparison of body composition at the indicated ages. (e,f) Water consumption and mean daily food intake were measured at the indicated ages. Data were analyzed by Student\'s *t*‐test (\*\**P* \< 0.01, *ihs* mice vs age‐matched B6).](JDI-10-227-g003){#jdi12895-fig-0003}

To assess whether the *ihs* mice were hyperphagic, the daily food intake was monitored in animals fed a standard chow diet *ad libitum*. At 12 and 25 weeks, the *ihs* mice consumed approximately 50% more food than the controls, indicating marked hyperphagia (Figure [3](#jdi12895-fig-0003){ref-type="fig"}e). In addition, a significant increase (*P* \< 0.05) in total water intake was observed in *ihs* mice throughout the experimental period (Figure [3](#jdi12895-fig-0003){ref-type="fig"}f). However, no proteinuria was observed and there were no obvious pathological changes in the glomeruli at 45 weeks‐of‐age in the male *ihs* mice (data not shown).

Glucose tolerance and insulin response to oral glucose loading and sensitivity to insulin {#jdi12895-sec-0017}
-----------------------------------------------------------------------------------------

To characterize the *ihs* mice in terms of systemic glucose homeostasis and insulin release *in vivo*, we carried out oral glucose tolerance tests (OGTTs) on *ihs* and control mice. At 10 weeks‐of‐age, there was no difference in fasting glucose levels between the *ihs* and control animals, but the male *ihs* mice showed typical glucose levels of ≥300 mg/dL, typical of diabetes, at 30--120 min after glucose loading (Figure [4](#jdi12895-fig-0004){ref-type="fig"}a). Although the female *ihs* mice showed normal blood glucose levels in the non‐fasting state, they showed marked impairment in glucose tolerance (Figure [4](#jdi12895-fig-0004){ref-type="fig"}b). The glucose AUC values after glucose loading in male and female *ihs* mice were significantly higher than those in B6 mice. Impaired glucose tolerance was observed in all male and female *ihs* mice with an exacerbation of glucose tolerance in an age‐dependent manner (Figure [S1](#jdi12895-sup-0001){ref-type="supplementary-material"}a,b).

![Glucose tolerance, insulin secretion and insulin sensitivity in *ihs* mice. (a,b) Upper figure: oral glucose tolerance test (2 g/kg) at 10--12 weeks‐of‐age in male B6 (*n* = 5) and *ihs* (*n* = 5) mice, and in female B6 (*n* = 6) and *ihs* (*n* = 5) mice. Blood glucose was measured at 0, 30, 60, 90 and 120 min in response to oral glucose administration in 16 h‐fasted mice. Lower figure: the area under the curve (AUC) of the 0--120 min glycemic responses. AUC~glucose~ was calculated using the trapezoidal rule. Data were analyzed by Student\'s *t*‐test (\*\**P* \< 0.01, *ihs* mice vs pair‐fed B6). (c,d) Upper figure: plasma insulin concentrations during the oral glucose tolerance tests (2 g/kg) at 10--12 weeks‐of‐age in male B6 (*n* = 5) and *ihs* (*n* = 4) mice, and in female B6 (*n* = 6) and *ihs* (*n* = 5) mice. Plasma insulin was measured at 0, 15 and 30 min in response to oral glucose administration in 16 h‐fasted mice. Lower figure: AUC~insulin~ of the 0--30 min % of initial value was calculated using the trapezoidal rule. Data were analyzed by Student\'s *t*‐test (\*\**P *\<* *0.01, *ihs* mice vs age‐matched B6). (e,f) Blood glucose (% of initial value) during the insulin tolerance test (0.75 IU/kg) at 10--12 weeks‐of‐age in male B6 (*n* = 6) and *ihs* (*n* = 8) mice, and in female B6 (*n* = 7) and *ihs* (*n* = 7) mice. The reverse AUC was calculated using the trapezoidal rule. Data were analyzed by Student\'s *t*‐test.](JDI-10-227-g004){#jdi12895-fig-0004}

Insulin concentrations were also measured during the OGTTs. The non‐fasting insulin levels (Figure [S2](#jdi12895-sup-0002){ref-type="supplementary-material"}) and the plasma insulin levels of the *ihs* and control mice before glucose administration were similar (Figure [4](#jdi12895-fig-0004){ref-type="fig"}c,d). After glucose loading, the *ihs* mice showed significantly lower insulin levels and the insulin AUC values were also lower (Figure [4](#jdi12895-fig-0004){ref-type="fig"}c,d). This suggested that *ihs* mice have defective glucose‐stimulated insulin secretion at the early phase of diabetes. Insulin release *in vivo* during the OGTTs was markedly impaired in male and female *ihs* mice, resulting in marked impairment in glucose tolerance. The plasma GLP‐1 levels after glucose loading in *ihs* mice was comparable with that of the control mice (Figure [S3](#jdi12895-sup-0003){ref-type="supplementary-material"}).

To test for insulin sensitivity, we carried out insulin tolerance tests on *ihs* and control mice (Figure [4](#jdi12895-fig-0004){ref-type="fig"}e,f). The *ihs* mice showed a normal glycemic response to exogenous insulin and were not insulin‐resistant.

Histological examination of pancreatic islets in male *ihs* mice {#jdi12895-sec-0018}
----------------------------------------------------------------

Islets from mutant and control mice at 10--12 weeks‐of‐age were of similar size and shape with a smooth periphery (Figure [5](#jdi12895-fig-0005){ref-type="fig"}a). No inflammation or fibroblast proliferation was observed in the mutant mouse islets. Immunostaining for insulin showed that insulin‐positive cells were regularly distributed. Furthermore, no differences in pancreatic insulin contents were observed between the mutant and control mice (Figure [5](#jdi12895-fig-0005){ref-type="fig"}b), and the sizes of individual β‐cells from the histological sections were similar in the mutant and control mice (Figure [5](#jdi12895-fig-0005){ref-type="fig"}c). Next, the volume of β‐cells relative to the gross volume of the pancreas was determined to analyze sections that were immunostained for insulin. In male *ihs* mice, the relative β‐cell volume was significantly lower than that in the control B6 mice (Figure [5](#jdi12895-fig-0005){ref-type="fig"}d), and the ratio of α/β‐cells in the *ihs* islets was significantly increased (Figure [5](#jdi12895-fig-0005){ref-type="fig"}e). In aged male and female *ihs* mice, the increase in α‐cells was more pronounced (Figures [S4](#jdi12895-sup-0004){ref-type="supplementary-material"} and [S5](#jdi12895-sup-0005){ref-type="supplementary-material"}); a marked decrease in the number of islets was observed only in aged male *ihs* mice. In mouse islets under normal conditions, α‐cells are localized in the islet periphery. However, the pattern of peripheral distribution of α‐cells seemed to be disrupted, and some α‐cells were scattered throughout the islet core in the pancreas of *ihs* mice in a manner similar to that observed in diabetes models (Figure [5](#jdi12895-fig-0005){ref-type="fig"}a)[15](#jdi12895-bib-0015){ref-type="ref"}.

![Pancreatic islet morphology. (a) Upper panels: pancreatic histological sections of male B6 and *ihs* mice at 10--12 weeks‐of‐age stained with hematoxylin--eosin (HE). Lower panels: immunohistochemistry with antibodies against insulin (green) and glucagon (red). (b) Insulin content, (c) β‐cell size, (d) Relative β‐cell volume (%) and (e) the ratio of α‐ to β‐cell areas in the pancreas (α/β‐ratio). B6 (*n* = 3) and *ihs* (*n* = 3) mice. Data were analyzed by Student\'s *t*‐test (\**P* \< 0.05, \*\**P* \< 0.01). Scale bar, 100 μm.](JDI-10-227-g005){#jdi12895-fig-0005}

Insulin secretion from perfused pancreata and isolated islets {#jdi12895-sec-0019}
-------------------------------------------------------------

We hypothesized that abnormal insulin secretion was the cause of the hypoinsulinemic hyperglycemia in the *ihs* mice. To test this, we carried out perfusion experiments that examined the time‐course of the insulin secretary response to high glucose. In the control pancreata, a change in glucose concentration from 2.8 to 16.5 mmol/L elicited strong peaks, with a 14‐fold increase in insulin secretion (Figure [6](#jdi12895-fig-0006){ref-type="fig"}a). As was expected from the results of the OGTTs, the elevation of glucose concentration from 2.8 to 16.5 mmol/L in the pancreata of the *ihs* mice resulted in a fourfold increase in insulin secretion. In the *ihs* mice, the AUC values of secreted insulin after glucose stimulation (from 10 to 26 min) was significantly impaired compared with that of the control mice (24.5 ± 9 vs 92.4 ± 13.1; *P *\< 0.01; Figure [6](#jdi12895-fig-0006){ref-type="fig"}b).

![Insulin secretion of perfused pancreata in response to high glucose and potassium chloride (KCl). (a) After a baseline period (10 min), glucose concentration in perfusate was shifted from 2.8 to 16.7 mmol/L for 15 min, and was then reduced to 2.8 mmol/L for 5 min, and 50 mmol/L KCl was then added to the perfusate. The amounts of secreted insulin in B6 (closed square, *n* = 4) and *ihs* (open square, *n* = 6) mice after stimulation with 16.7 mmol/L glucose and KCl are expressed as the area under the curve for insulin (AUC~insulin~) from 10 to 26 min and 35 to 40 min, respectively. (b) The AUCs were assessed for insulin levels in the perfusate (AUC~insulin~) using the trapezoidal rule of suprabasal values. Data were analyzed by Student\'s *t*‐test (\**P *\< 0.05, \*\**P* \< 0.01).](JDI-10-227-g006){#jdi12895-fig-0006}

Islet β‐cell glucose metabolism is accompanied by closure of the adenosine triphosphate‐sensitive potassium channels followed by depolarization. We therefore investigated insulin secretion in response to potassium chloride (KCl), a potent insulin secretagogue, to identify which steps in the insulin secretion pathway are impaired in *ihs* mice. The *ihs* pancreata showed a significantly lower increase in insulin secretion compared with the control pancreata (an 8‐fold increase vs a 47‐fold increase; *P *\< 0.05; Figure [6](#jdi12895-fig-0006){ref-type="fig"}a), indicating a significant reduction in insulin secretion in the *ihs* mice (Figure [6](#jdi12895-fig-0006){ref-type="fig"}b). In the batch incubation experiment, the islets isolated from *ihs* mice also showed a significant decrease in insulin secretion compared with those isolated from control mice, when stimulated with glibenclamide, (antidiabetic drug of class sulfonylureas), which causes the β‐cell depolarization (Figure [S6](#jdi12895-sup-0006){ref-type="supplementary-material"})[16](#jdi12895-bib-0016){ref-type="ref"}. These results showed that the insulin secretion capability of β‐cells was markedly impaired in *ihs* mice.

Assessment of pancreatic β‐cell gene expression in the islets of *ihs* and control mice {#jdi12895-sec-0020}
---------------------------------------------------------------------------------------

Glucose‐stimulated insulin secretion can be impaired after a reduction in the proteins involved in glucose sensing and insulin secretion. To determine whether the defect in insulin secretion in *ihs* mice was associated with abnormalities in gene transcription, the expression of pancreatic β‐cell‐specific genes or genes associated with monogenic diabetes was assessed by RT‐qPCR (Figure [7](#jdi12895-fig-0007){ref-type="fig"}). Most of these genes showed no change in expression in comparison with control mice. However, *Glp1r* was significantly upregulated, and the expression levels of *Glis3*,*Glut2*,*Wfs1* and *Epac2* were downregulated, in the islets of the *ihs* mice.

![Comparison of the expression of diabetes‐related genes between islets from B6 and *ihs* mice. RT‐qPCR analysis of diabetes‐related genes for isolated *ihs* islets at 10 weeks‐of‐age. The values were arbitrary units after normalization against *Actb*. All data are expressed as mean ± standard error of the mean, and data were analyzed by Student\'s *t*‐test (\**P* \< 0.05, \*\**P* \< 0.01). B6 (*n* = 3) and *ihs* (*n* = 3) mice. Each experiment was carried out in three biological replicates.](JDI-10-227-g007){#jdi12895-fig-0007}

Discussion {#jdi12895-sec-0021}
==========

Animal models of diabetes that more closely recapitulate the features of the human disease would be useful for understanding the pathogenesis and developing new treatment strategies. The *ihs* mice showed several distinctive diabetes‐related characteristics: (i) the onset of diabetes was observed only in the male mice; (ii) there were no differences in insulin content between the *ihs* and control mice; (iii) impaired insulin secretion was elicited by glucose and KCl; (iv) there was a significant reduction of relative β‐cell volume with no signs of inflammation or fibrosis; (v) they showed a normal glycemic response to exogenous insulin; and (vi) they were non‐obese. Nagoya--Shibata--Yasuda (NSY) mice, a type 2 diabetes model derived from ICR mice, showed phenotypes similar to that of *ihs* mice, such as severely impaired glucose tolerance, reduction in glucose‐stimulated insulin secretion and differences in diabetes onset based on sex[17](#jdi12895-bib-0017){ref-type="ref"}, [18](#jdi12895-bib-0018){ref-type="ref"}, [19](#jdi12895-bib-0019){ref-type="ref"}, [20](#jdi12895-bib-0020){ref-type="ref"}. However, NSY mice showed an increase in the fasting plasma insulin levels, insulin resistance and hypertrophy of pancreatic islets, whereas *ihs* mice had normal fasting plasma insulin levels and insulin sensitivity, and showed the relative β‐cell volume was lower than that in control mice. Furthermore, the incidence of diabetes in the female NSY mice was 31% at 48 weeks, whereas the female *ihs* mice did not develop diabetes, although female *ihs* mice have impaired glucose tolerance. Therefore, we concluded that the *ihs* mouse was a novel murine model for non‐obese type 2 diabetes.

The release of insulin from pancreatic β‐cells is regulated by highly complex and sophisticated mechanisms, modulated by many factors, including hormones, neuropeptides and neurotransmitters[21](#jdi12895-bib-0021){ref-type="ref"}. With respect to the mechanism in β‐cells, we showed that *Glut2*,*Wfs1* and *Epac2* expression levels were significantly downregulated (by 50%) in the islets of the *ihs* mice, and that *Glp1r* expression was increased threefold. The GLP‐1 receptor (GLP1R) is expressed mainly in the alimentary tract, particularly in the pancreatic islet cells[22](#jdi12895-bib-0022){ref-type="ref"}, where it mediates the actions of GLP‐1 released from the small intestines in response to food intake. GLP‐1 is considered to be one of the most important glucose‐dependent insulin secretagogues[23](#jdi12895-bib-0023){ref-type="ref"}, and is known to cause a rise in intracellular Ca^2+^ concentration[24](#jdi12895-bib-0024){ref-type="ref"}. The GLP1R, a G‐protein‐coupled receptor, is involved in insulin secretion through mechanisms dependent on and independent of PKA[25](#jdi12895-bib-0025){ref-type="ref"}. GLP‐1 stimulates the expression of glucose transporter 2, which determines the rate of glycolysis and helps to confer the glucose competence to β‐cells, thereby increasing the efficacy and potency of glucose as a stimulus for insulin secretion[25](#jdi12895-bib-0025){ref-type="ref"}. It has been reported that WFS1 is essential for GLP‐1‐stimulated cAMP production, and the regulation of insulin biosynthesis and secretion[26](#jdi12895-bib-0026){ref-type="ref"}. In pancreatic β‐cells, cAMP signaling, which can be activated by various extracellular stimuli, including hormonal and neural inputs primarily through G‐protein‐coupled receptors, is vital for the normal regulation of insulin secretion to maintain glucose homeostasis. The activation of cAMP signaling amplifies insulin secretion dependent on exchange protein directly activated by cAMP 2 (EPAC2)[27](#jdi12895-bib-0027){ref-type="ref"}. EPAC2 is essential in the potentiation of insulin granule exocytosis by cAMP, primarily in the first phase of cAMP‐potentiated exocytosis, by increasing the number of restless newcomers[27](#jdi12895-bib-0027){ref-type="ref"}. Although the plasma GLP‐1 concentration was comparable with the control mouse (Figure [S3](#jdi12895-sup-0003){ref-type="supplementary-material"}), the unresponsiveness of the pathway induced by GLP1R activation might cause the upregulation of *Glp1r*, and downregulation of *Glut2*,*Wfs1* and *Epac2* expression in the *ihs* mouse.

A high concentration of KCl and sulfonylureas can directly cause depolarization of the β‐cell plasma membrane, which subsequently triggers an influx of Ca^2+^ and insulin granule exocytosis[16](#jdi12895-bib-0016){ref-type="ref"}, [28](#jdi12895-bib-0028){ref-type="ref"}. This indicates that the defective insulin release induced by KCl in the perfusion experiments (Figure [6](#jdi12895-fig-0006){ref-type="fig"}) and by glibenclamide in batch incubation experiments (Figure [S6](#jdi12895-sup-0006){ref-type="supplementary-material"}) was not caused by a defect in GLP‐1 signaling. The causative gene for insulin hyposecretion in the *ihs* mouse is not involved in incretin‐potentiated insulin secretion. However, the GLP‐1 signal elevates cytosolic Ca^2+^ in β‐cells[24](#jdi12895-bib-0024){ref-type="ref"}, [29](#jdi12895-bib-0029){ref-type="ref"}. Thus, the significant upregulation of *Glp1r* and marked impairment of insulin secretion stimulated by glucose and KCl might be caused by a defect in the Ca^2+^ signaling pathway in the β‐cells of the *ihs* mice. Although relative β‐cell volume of *ihs* mice decreased to almost 60% of that of the B6 mice (Figure [5](#jdi12895-fig-0005){ref-type="fig"}d), no differences were observed in the insulin content of the pancreata and in the β‐cell size between the *ihs* and control mice (Figure [5](#jdi12895-fig-0005){ref-type="fig"}b,c), and insulin 1 and 2 mRNA levels were similar in the two strains (Figure [6](#jdi12895-fig-0006){ref-type="fig"}). This suggests the possibility that more insulin granules are stocked in each β‐cell of *ihs* mice. Therefore, we concluded that the marked dysfunction in insulin secretion observed in the *ihs* mice at a young age was not caused by a defect in the insulin production or islet architecture and organization, but by a defect in the Ca^2+^ influx and/or Ca^2+^ signaling pathway in β‐cells.

The incidence of diabetes in the male *ihs* mice was 90% at 42 weeks‐of‐age; in contrast, none of the female mice developed diabetes, even though the female *ihs* mice showed impaired glucose tolerance and the impairment of glucose‐induced insulin secretion (Figures [4](#jdi12895-fig-0004){ref-type="fig"}b,d and [S1](#jdi12895-sup-0001){ref-type="supplementary-material"}b). In the present study, we found that the relative β‐cell volume in the male *ihs* mice was lower than that in age‐matched B6 mice (Figure [5](#jdi12895-fig-0005){ref-type="fig"}d), and progressively decreased with aging (Figure [S4](#jdi12895-sup-0004){ref-type="supplementary-material"}). In contrast, marked reduction of islets was not observed in aged female *ihs* mice (Figure [S5](#jdi12895-sup-0005){ref-type="supplementary-material"}). It seemed that the reduction of islets in aged male *ihs* mice was influenced by glucotoxicity. Additionally, glucagon‐positive α‐cells were evenly distributed along the periphery of the islets in the control mice. However, a relative increase in α‐cells along the periphery and in the central core of the islet was more evident with aging in the male and female *ihs* mice (Figures [S4](#jdi12895-sup-0004){ref-type="supplementary-material"} and [S5](#jdi12895-sup-0005){ref-type="supplementary-material"}). A relative increase in α‐cells has been reported in many animal models with β‐cell deficiency[15](#jdi12895-bib-0015){ref-type="ref"}, as well as in patients with type 2 diabetes[30](#jdi12895-bib-0030){ref-type="ref"}, [31](#jdi12895-bib-0031){ref-type="ref"}. This is thought to result from the collapse of the central β‐cell core due to the loss of β‐cells rather than from α‐cell hyperplasia. A similar sex difference has been observed in a variety of diabetic cases in humans[32](#jdi12895-bib-0032){ref-type="ref"}, [33](#jdi12895-bib-0033){ref-type="ref"}. In addition, many knockout and transgenic models of diabetes show a sex bias[34](#jdi12895-bib-0034){ref-type="ref"}, and the protective effect of estradiol against the development of insulin resistance and diabetes has been widely discussed[35](#jdi12895-bib-0035){ref-type="ref"}, [36](#jdi12895-bib-0036){ref-type="ref"}. We assume that estrogen and prolactin play a protective role in female rodents, as they have a regulatory influence on β‐cell function[37](#jdi12895-bib-0037){ref-type="ref"} and proliferation rates[38](#jdi12895-bib-0038){ref-type="ref"}. Further research is warranted to elucidate the mechanism(s) underlying this sex bias.

Models of spontaneous diabetes are invaluable for the identification of unknown diabetogenic genes. The *ihs* mouse model involves neither obesity nor insulitis, but is accompanied by notable pancreatic β‐cell dysfunction, which distinguishes it from other well‐characterized animal models. Although further genetic analysis is required to allow a better understanding of the molecular pathology of *ihs* mice, our preliminary exome sequencing analysis from ICGN mice and genetic analysis in *ihs* mice showed no non‐synonymous, nonsense or frameshift mutations in the known genes responsible for monogenic diabetes characterized by β‐cell failure in humans and rodents. This suggests that the *ihs* strain can contribute to the discovery of novel causative genes, potentially leading to the development of treatment strategies for hypoinsulinemia and diabetes.
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**Figure S1** ¦ Glucose tolerance test in *ihs* mice at each weeks of age.
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**Figure S2** ¦ Non‐fasting plasma insulin levels.
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**Figure S3** ¦ Plasma active GLP‐1 levels after glucose oral administration.
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**Figure S4** ¦ Pancreatic islet morphology in aged male *ihs* mice.
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**Figure S5** ¦ Pancreatic islet morphology in female *ihs* mice**.**
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**Figure S6** ¦ Insulin secretion in the isolated islets of *ihs* mice.
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**Table  S1** ¦ RT‐qPCR primer sets of genes associated with monogenic diabetes.
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**Appendix S1** ¦ Mice.

**Appendix S2** ¦ Non‐fasting plasma insulin levels.

**Appendix S3** ¦ Plasma active GLP‐1 levels.

**Appendix S4** ¦ Insulin secretion from the *in situ* perfused pancreas.

**Appendix S5** ¦ Insulin secretion of islets isolated from *ihs* mice.

**Appendix S6** ¦ Islet morphology analysis.

**Appendix S7** ¦ RT‐qPCR analysis.
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